Grant/RFP Opportunities

UCB, Inc. Medical Affairs Request for Proposal (RFP)

Deadline Date: October 24, 2014
RFP Number:
Area of Interest: Systemic Lupus Erythematosus
Purpose of Request for Proposal (RFP): 
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The US organization, UCB, Inc, is considering proposals for a comprehensive, multi-part, phased curriculum of CME accredited (ACCME, AOA, AMA, AAFP or ADA CERP) educational programs to address gaps in the existing knowledge of health care professionals over the course of 2015. Proposals should be designed to ultimately improve health outcomes in patients with systemic lupus erythematosus (SLE). Programs may include but should not necessarily be limited to understanding of the disease burden and the impact of poorly controlled disease activity on patients, healthcare systems and society, as well as disease management considerations including treatment goals and optimization of therapy across all involved body systems. Treatment goals should be considered from the patient and clinician perspective and include disease activity measures and the applicability of broad treat to target concepts in lupus. The program objectives are to improve patient care in daily practice, enhance practical application of evidence based data to optimize the management of SLE patients with diverse manifestations of disease, advance understanding of the impact of disease activity on patient outcomes, and increase clinician collaboration with patients for shared treatment goals. Proposals should include a mixture of live and online activities, incorporate an array of different media, contain enduring materials, and utilize a case based approach to learning wherever possible. The audience is rheumatologists treating patients with SLE.
The budget for this program is $450,000-550,000 (UCB sole support).